Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Equities researchers at Zacks Research increased their Q2 2025 earnings estimates for shares of Teva Pharmaceutical Industries in a research report issued on Thursday, April 3rd. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.61 per share for the quarter, up from their previous estimate of $0.60. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q2 2025 earnings at $0.61 EPS, Q3 2025 earnings at $0.71 EPS, Q3 2025 earnings at $0.71 EPS, Q1 2027 earnings at $0.62 EPS and Q1 2027 earnings at $0.62 EPS.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%.
A number of other equities research analysts have also recently issued reports on the stock. Piper Sandler upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. UBS Group lowered their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Bank of America dropped their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Friday, April 4th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $23.43.
Get Our Latest Research Report on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Stock Performance
Shares of Teva Pharmaceutical Industries stock traded up $0.30 on Friday, reaching $13.89. The stock had a trading volume of 14,078,068 shares, compared to its average volume of 9,820,766. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The business's 50-day moving average price is $16.10 and its two-hundred day moving average price is $17.93. The stock has a market cap of $15.74 billion, a P/E ratio of -9.59, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries has a fifty-two week low of $12.51 and a fifty-two week high of $22.80.
Institutional Investors Weigh In On Teva Pharmaceutical Industries
Several institutional investors and hedge funds have recently bought and sold shares of TEVA. Oarsman Capital Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $44,000. Wilmington Savings Fund Society FSB acquired a new stake in Teva Pharmaceutical Industries in the third quarter worth $50,000. Ameliora Wealth Management Ltd. acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter worth $66,000. Finally, Versant Capital Management Inc grew its position in shares of Teva Pharmaceutical Industries by 437.8% in the 1st quarter. Versant Capital Management Inc now owns 5,297 shares of the company's stock valued at $81,000 after purchasing an additional 4,312 shares during the period. Institutional investors own 54.05% of the company's stock.
Teva Pharmaceutical Industries Company Profile
(
Get Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
See Also
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
